Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Macimorelin
View:
Post by Alex1726 on Jan 20, 2024 9:00pm

Macimorelin

Approved Macimorelin to treat AGHD and CGHD in advanced phase III showing very poromising potential to reach market is to my humble opinion by now a  more de-risked asset than PGX could be.

We do not know what will happen with Pressurized Gas eXpanded Technology (PGX).

If PGX does not deliver goods results, CZO does not worth much , it is a real good familly business , and developping the technology might be much more cap-ex than what was known, anyway we"ll never know the real issues with Gagnon.

Comment by Alex1726 on Jan 20, 2024 9:11pm
Macimorelin could be a very valuable asset , maybe more than PGX. Make your own opinion and share it. https://www.evaluate.com/vantage/articles/news/deals/flipping-win-strongbridge-biopharma
Comment by Ciao on Jan 21, 2024 10:46am
Based on PGX CoQ10 results published in Oct., 2023 I would say that PGX could easily attract a partner to fund the next commercial stage, so it definitely has more potential esp. given that PGX is a delivery system for bioactives with endless possibilities. https://stockhouse.com/news/press-releases/2022/10/13/ceapro-inc-announces-positive-data-from-bioavailability-studies-evaluating-coq10 We ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities